Reistone Biopharma is a clinical stage biopharmaceutical company that collaborates with key stakeholders and leading pharmaceutical companies to develop new medicines for life-threatening autoimmune diseases. Their focus is on inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD), as well as dermatology diseases like atopic dermatitis. They are developing small molecule drugs, including JAK and BTK inhibitors, to target these inflammatory diseases. Their flagship product, SHR0302, is intended for the treatment of atopic dermatitis, and they are also working on drugs for vitiligo, ulcerative colitis, and Crohn's disease.